Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management (Q38504254)

3 September 2017

1 reference

title

Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management (English)

1 reference

3 September 2017

0 references

0 references

1 reference

P Manu

1

1 reference

3 September 2017

L Dima

2

1 reference

3 September 2017

M Shulman

3

1 reference

3 September 2017

D Vancampfort

4

1 reference

3 September 2017

M De Hert

5

1 reference

3 September 2017

C U Correll

6

1 reference

3 September 2017

language of work or name

English

0 references

publication date

27 May 2015

1 reference

Acta Psychiatrica Scandinavica

3 September 2017

published in

1 reference

3 September 2017

volume

132

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

97-108

1 reference

Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials.

3 September 2017

cites work

1 reference

Body mass index identified as an independent predictor of psychiatric readmission.

21 January 2018

1 reference

Antipsychotic drugs and obesity

21 January 2018

1 reference

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

21 January 2018

1 reference

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis

21 January 2018

1 reference

Developmental obesity and schizophrenia.

21 January 2018

1 reference

Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013

21 January 2018

1 reference

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society

21 January 2018

1 reference

Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder.

21 January 2018

1 reference

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis

21 January 2018

1 reference

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons

21 January 2018

1 reference

Weight effects associated with antipsychotics: a comprehensive database analysis

21 January 2018

1 reference

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database

21 January 2018

1 reference

Weight gain in antipsychotic-naive patients: a review and meta-analysis

21 January 2018

1 reference

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

21 January 2018

1 reference

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis

21 January 2018

1 reference

Almost all antipsychotics result in weight gain: a meta-analysis

21 January 2018

1 reference

Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.

21 January 2018

1 reference

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

21 January 2018

1 reference

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

21 January 2018

1 reference

Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents

21 January 2018

1 reference

Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials

21 January 2018

1 reference

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

21 January 2018

1 reference

Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.

21 January 2018

1 reference

Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis

21 January 2018

1 reference

Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine

21 January 2018

1 reference

Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents

21 January 2018

1 reference

Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons

21 January 2018

1 reference

Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean?

21 January 2018

1 reference

Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database

21 January 2018

1 reference

Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials

21 January 2018

1 reference

Serum leptin and its relationship with psychopathology in schizophrenia

21 January 2018

1 reference

Contribution of baseline body mass index and leptin serum level to the prediction of early weight gain with atypical antipsychotics in schizophrenia

21 January 2018

1 reference

American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults

21 January 2018

1 reference

The dietary pattern of patients with schizophrenia: a systematic review

21 January 2018

1 reference

Unhealthy lifestyle in early psychoses: the role of life stress and the hypothalamic-pituitary-adrenal axis

21 January 2018

1 reference

Nutritional status, food intake and cardiovascular disease risk in individuals with schizophrenia in southern Brazil: a case-control study

21 January 2018

1 reference

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design

21 January 2018

1 reference

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics

21 January 2018

1 reference

Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication

21 January 2018

1 reference

Low-fat oxidation may be a factor in obesity among men with schizophrenia

21 January 2018

1 reference

Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis

21 January 2018

1 reference

Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia

21 January 2018

1 reference

Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain

21 January 2018

1 reference

Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats

21 January 2018

1 reference

A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study.

21 January 2018

1 reference

Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study

21 January 2018

1 reference

Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight

21 January 2018

1 reference

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

21 January 2018

1 reference

The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?

21 January 2018

1 reference

Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats

21 January 2018

1 reference

Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment

21 January 2018

1 reference

Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination

21 January 2018

1 reference

Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain

21 January 2018

1 reference

Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients.

21 January 2018

1 reference

Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain

21 January 2018

1 reference

Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia

21 January 2018

1 reference

Markers of inflammation in schizophrenia: association vs. causation

21 January 2018

1 reference

Genetic association between TNF-alpha -308 G>A polymorphism and longitudinal weight change during clozapine treatment

21 January 2018

1 reference

TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment

21 January 2018

1 reference

A behavioral weight-loss intervention in persons with serious mental illness

21 January 2018

1 reference

Marital and labor market status in the long run in schizophrenia

21 January 2018

1 reference

Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey

21 January 2018

1 reference

21 January 2018

1 reference

Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes

21 January 2018

1 reference

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

21 January 2018

1 reference

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis

21 January 2018

1 reference

Management of antipsychotic-related weight gain

21 January 2018

1 reference

Metabolic syndrome associated with schizophrenia and atypical antipsychotics

21 January 2018

1 reference

The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial

21 January 2018

1 reference

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

21 January 2018

1 reference

The association between weight change and symptom reduction in the CATIE schizophrenia trial

21 January 2018

1 reference

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)

21 January 2018

1 reference

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

21 January 2018

1 reference

Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone

21 January 2018

1 reference

Safety and tolerability of antipsychotic polypharmacy

21 January 2018

1 reference

Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study

21 January 2018

1 reference

Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?

21 January 2018

1 reference

Physical illness and schizophrenia: a review of the literature

21 January 2018

1 reference

Emerging drugs for schizophrenia: an update

21 January 2018

1 reference

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

Antipsychotic treatment and mortality in schizophrenia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ACPS.12445

1 reference

3 September 2017

1 reference